Completed PHASE1 INTERVENTIONAL 2-arm NCT05491421

A Study of ZT002 in Healthy Participants

A Phase 1, Randomized, Parallel Assignment, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of ZT002 in Healthy Participants

Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

Conditions Type 2 Diabetes Mellitus

Interventions Placebo ZT002

Updated 5 times since 2022 Last updated: Jan 14, 2026 Started: Sep 2, 2022 Primary completion: Apr 28, 2023 Completion: Apr 28, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05491421, this PHASE1 trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by Beijing QL Biopharmaceutical Co.,Ltd, it has been updated 5 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1

Status: Unknown → Completed
Sep 2024 — Feb 2026 [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jun 2023 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Jun 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing QL Biopharmaceutical Co.,Ltd
Novotech (Australia) Pty Limited
QL Biopharmaceutical Australia Pty Ltd

Data source: Beijing QL Biopharmaceutical Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Herston, Australia